The Food & Drug Administration today announced a program for improving the safety and efficacy of automated external defibrillators.
The federal watchdog agency said it’s received 28,000 reports of AED failures in the last five years, yet 300,000 Americans could benefit from treatment from the devices every year.
AEDs are designed to treat cardiac arrest and both diagnose and treat abnormal heart rhythms. While some external defibrillators and intended for medical professionals, AEDs are turning up in homes and public locations with simpler designs.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The FDA’s Center for Devices and Radiological Health, which is running the External Defibrillator Improvement Initiative, said many of the problems associated with the devices are preventable and include engineering and manufacturing issues related to “adequate control of components bought from other suppliers.”
Through the AED program, the CDRH hopes to designate an “appropriate” premarket approval protocol for AEDs that promotes improved design and testing practices, according to the FDA. The agency also hopes to enhance its ability to collaborate with AED manufacturers on identifying problems with devices currently on the market.
In recent months, Zoll Medical Corp. (NASDAQ:ZOLL) and Philips Healthcare have both dealt with safety issues related to their external defibrillators, which led to recalls. Other companies that manufacture the devices include Cardiac Science Corp. (NASDAQ:CSCX), Defibtech, Welch Allyn Inc., HeartSine Technologies Inc. and Medtronic Inc. (NYSE:MDT) subsidiary Physio-Control Inc.
The CDRH intends to hold a meeting for the initiative Dec. 15 and 16 at FDA headquarters near Washington, D.C.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
